EPM

Our mission is to bridge the cannabis & pharmaceutical industries by increasing the potential development in cannabinoid-based pharmaceutical therapeutics.

[EPM @epmip]

היי, אנחנו epm 👋

אל תסתפקו בכותרות באתרים!

אנחנו כאן כדי לדבר איתכם ולספק את כל המידע על ההנפקה הנגישה של החברה שנמצאת בעיצומה בימים אלה.

בואו להכיר אותנו מקרוב:

לעמוד ההנפקה>>https://t.co/jZIi66mtjH

לקבלת כל המידע באופן אישי>>https://t.co/HcRBGS0zWY

עקבו אחרינו לעדכונים.

[IPWSO @ipwso]

Welcome to our delegates as you start to arrive for #IPWSO2022 with @PWSAI! Many thanks to our sponsors for making this event possible. @novonordisk @Radius_Health @fpwr @PWSAUSA @friendsofipwso @Saniona_AB Soleno Therapeutics @OT4Bfrance @epmip Aardvark Therapeutics

[EPM @epmip]

קצת על המדע מאחורי החברה:

המחקרים והפיתוח מתבצעים בשיתוף עם אוניברסיטאות וחוקרים בעלי שם עולמי כגון:

פרופ' דן פאר (אוני׳ תל-אביב),
פרופ' יוסף (יוסי) תם (האוני׳ העברית),
פרופ' מרק בראון (מדפארם) ועוד...

עוד על שיתופי הפעולה והמחקרים האקדמיים, פה>>https://t.co/HFFFiAKIpp

[EPM @epmip]

הנהלת החברה מתכבדת להכריז כי ההנפקה של EPM נפתחה מחדש בהצעה אחידה להזמנות הציבור.

החברה ביצעה התאמות תוכן באתר Fundit ופרסמה תיקון תשקיף.

לתשקיף החברה>>https://t.co/4rQSnzMLic

לעמוד ההנפקה>>https://t.co/jZIi66mtjH

מוזמנים להכנס ולעקוב.

[EPM @epmip]

An inspiring interview with Prof. Mechoulam and EPM about a new compound, EPM301, representing the future of cannabinoid acids as new medicine and potential alternative to steroid treatments.

[Javier Hasse @JavierHasse]

More Potent Than CBD, THC: Dr. Raphael Mechoulam Explains His Latest Discovery
My latest for @Forbes
https://t.co/3u0EK1yeLE

[Javier Hasse @JavierHasse]

More Potent Than CBD, THC: Dr. Raphael Mechoulam Explains His Latest Discovery
My latest for @Forbes
https://t.co/3u0EK1yeLE

[Michael Miller - LA Weekly & CannaBusiness @CannaBusinessMM]

An extraordinary interviewers rock star fantasy. The Mick Jaggers of cannabis science and business two countries same week. #cannamed #canex #laweekly #benzinga

[MERRY JANE @MERRYJANE]

Dr. Raphael Mechoulam has discovered a way to create safe and stable synthetic acid forms of THC and CBD, opening the doors for a wide range of new medical treatments. 👨🏻‍⚕️🧬🔬🧪
https://t.co/hM3ChmK32b

[NBC News Health @NBCNewsHealth]

Cannabis research pioneer hopes latest discovery is not overlooked — again https://t.co/2kw4pPTRJG

[EPM @epmip]

Great discussion and collaboration at #CannMed2019! Learn more about EPM’s research, how our scientific team was able to industrialize a formula to manufacture stable #cannabinoid acids commercially, and how we are sharing the use of our molecules: https://t.co/3HV3Qd1Jlk

[EPM @epmip]

Prof. Dan Peer explains preclinical data presented at #CannMed2019 that shows promise of #cannabinoid acids in treating #IBD in animal models at @CannMedEvents.

#CannMed2019 | #CannMedinspires | #CannabisScience| #CannabisHealth | #CannabisConference

[EPM @epmip]

Prof. Joseph Tam presented data at @CannMedEvents on the potential therapeutic benefits of #cannabinoidacids shown in animal models on diabetes-induced metabolic abnormalities.

#CannMed2019 | #CannMedinspires | #CannabisScience| #CannabisHealth | #CannabisConference

[EPM @epmip]

Check out EPM’s CEO Reshef Swisa, speaking to @CannaBusinessMM of @LAWeekly about our mission to bridge the #cannabis and pharmaceutical industries through the company’s new therapeutics development platform. @Benzinga @MediGenomics #CannMedInspires | #CannMed2019

[EPM @epmip]

@endpts We believe our development of synthetic, fully stable acid-based cannabinoid molecules will be an important bridge for the research and development of potential new therapies. #CannMed2019

[EPM @epmip]

For the first time ever, pharmaceutical companies will have access to a wide variety of patent protected, stable cannabinoid molecules synthesized to provide stability and consistency for use in developing new medicines.

[Endpoints News @endpts]

Startup EPM launches, high off acid-based cannabinoid innovation https://t.co/56eVJoHOio

[EPM @epmip]

“We have taken the unstable acid molecules of the cannabis plant and synthesized them to provide a stable, consistent basis for researching new therapies across a wide range of medical needs.” – Prof. Raphael Mechoulam, PhD, head of research, EPM

#CannMedInspires #CannMed2019

[EPM @epmip]

#NEWS: Today marks the start of a new era in medical research as EPM introduces an innovative development platform for the use of our fully stable acid-based #cannabinoid molecules at #CannMed2019. Learn more: https://t.co/hEwVXpG8uI #CannMedInspires

[CannMed @CannMedEvents]

BIG NEWS! Prof. Raphael Mechoulam's keynote at CannMed 2019 will discuss development of new family of stabilized cannabinoid acids. Industry changing. One of last trips to US - are YOU coming to CannMed? Buy NOW!
https://t.co/GOhm7czHEN

@CannMedEvents @MediGenomics @ProjectCBD

[EPM @epmip]

Prof. Dan Peer discusses how the company is at the forefront of pioneering #cannabinoid acid research with the potential to impact human health.

#CannMedInspires | #CannabisScience| #CannabisHealth | #CannabisConference | #CannMed2019

[EPM @epmip]

The father of #cannabis research and #CannMed2019 keynote speaker, Dr. Raphael Mechoulam, explains EPM’s unprecedented work in #cannabinoid acid molecules.

#CannMedInspires | #CannabisScience| #CannabisHealth | #CannabisConference